As the industry prepared for the first deluge of American Society of Clinical Oncology (ASCO) data Thursday night, cancer drug company Allos Therapeutics Inc. managed to capture a little attention of its own early in the day by reporting promising interim data from its pivotal Phase II study of PDX (pralatrexate) in peripheral T-cell lymphoma (PTCL). (BioWorld Today)
Less than two days after Amgen Inc. said it was picking up a Phase II-stage drug for chronic kidney disease through the acquisition of Ilypsa Inc., the biotech giant announced plans to swallow another small biotech, Alantos Pharmaceuticals Inc., for $300 million cash. (BioWorld Today)
Four months after GPC Biotech AG's satraplatin met its endpoint in a pivotal prostate cancer study, the company pulled in €33.6 million (US$43.7 million) to pave the way for the compound's anticipated commercialization. (BioWorld Today)
